Mesoblast offers an extraordinary gap between current price and analyst consensus — over 116% potential upside at roughly 34-to-1 reward versus geometric downside — but the stock is in a falling-knife formation, burns cash at over 100% of revenues, operates with zero reported margins, and quality scores well below minimum thresholds; the asymmetric geometry is notable but the entry setup is not confirmed.
Thesis pillars
- Cash Burn Zero Margin Profile→Stable
- Extreme Asymmetric Upside Geometry↓Deteriorating
- Falling Knife Technical Profile→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Mesoblast Limited (MESO) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $14.29, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Elevated risk factors.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil... Read more
Hold if already holding. Not a fresh buy at $14.29, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Elevated risk factors. Chart setup: Death cross but MACD improving, RSI 52. Mixed signals. Hold existing position. Score 5.8/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 112d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 5, 2026Recent Developments — Mesoblast Limited
Latest news
- NEWS Mesoblast Hosts Key Opinion Leader Webinar on Graft-versus-Host Disease — fiscal.ai Nov 5, 2026 neutral
- NEWS Mesoblast highlights Ryoncil as first-line trea... - Pluang — Pluang Nov 5, 2026 positive
- NEWS Mesoblast stock set for board refresh as two directors depart - ad-hoc-news.de — ad-hoc-news.de Nov 3, 2026 negative
- NEWS Mesoblast Reports Director Departure and ASX Filings - TipRanks — TipRanks Nov 3, 2026 neutral
- NEWS Mesoblast Announces Board Rotational Changes and Retirements — fiscal.ai Nov 2, 2026 neutral
Latest item Nov 5, 2026 · Generated 2026-11-05T11:44:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $14.29, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Elevated risk factors. Chart setup: Death cross but MACD improving, RSI 52. Mixed signals. Hold existing position. Analyst target $31.45 (+120.1%), stop $13.29 (−7.5%), A.R:R 8.0:1. Score 5.8/10, moderate confidence.
Analyst target: $31.45 (+120.1% upside). Analyst target $31.45 (+120.1%), stop $13.29 (−7.5%), A.R:R 8.0:1. Stop-loss: $13.29.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Elevated risk factors; Below 200-MA, MA slope -4.4%/30d (confirmed downtrend).
Mesoblast Limited trades at a P/E of N/A (forward 31.4). TrendMatrix value score: 4.1/10. Verdict: Hold.
10 analysts rate MESO, with a consensus score of 4.1/5. 2 analysts publish price targets averaging $37.
What does Mesoblast Limited do?Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in...
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.